Kodiak discontinues tarcocimab after Phase 3 DME studies fail to meet endpoints; DAYLIGHT meets primary endpoint

Kodiak Sciences Inc.

Cash and equivalents $379M as of June 30, 2023 (unaudited).
DAYLIGHT study in wet AMD met primary endpoint of non‑inferior visual acuity gains vs aflibercept.
GLEAM and GLIMMER DME studies did not meet primary efficacy endpoint; tarcocimab letters gained 6.4 vs 10.3 (GLEAM) and 7.4 vs 12.2 (GLIMMER).
Cataract adverse events at 19% on tarcocimab vs 9% on aflibercept in pooled DME safety population; no vasculitis or occlusion.
Company discontinues further development of tarcocimab based on these data.

item 2.02 item 8.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Kodiak Sciences Inc. reported preliminary financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: preliminary results

Exact text from the filing

On July 24, 2023, Kodiak Sciences Inc. (“Kodiak,” or the “Company”) reported that, as of June 30, 2023 (unaudited), the Company had approximately $379 million in cash and cash equivalents.

View on SEC.gov

Browse all earnings releases →

Kodiak Sciences Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-033933

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.